NasdaqGM · Biotechnology

Wave Life Sciences (WVE)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+260.3%

$19.06 average target

$5.29+0.04 (+0.8%)Latest market snapshot · Yahoo Finance

Market cap$1.04B

Cash$490.6M

Quarterly burn$53.6M

Pipeline assets8

Short float10.3%

Clinical portfolio

Wave Life Sciences Drug Pipeline

Showing 0 of 8

Pipeline data is not currently available

The page remains usable with the verified company and catalyst data already on file.

Continue with BioPharma ProUnlock 8 additional programs and complete development details.

Unlock Pro

Upcoming milestones

WVE Catalyst Timeline

0 currently tracked

Dated catalysts is not currently available

The page remains usable with the verified company and catalyst data already on file.

Company profile

About Wave Life Sciences

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.